Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement

Actinogen Medical Limited

Ongoing development of Xanamem, a unique inhibitor of the 11B-HSD1 enzyme that achieves target engagement in the central nervous system.

ACW$0.029
 0.001 3.57%

Data last updated:May 14, 2024 – 4.11pm. Data is 20 mins delayed.

Previous Close

0.028

Open

0.028

Day Range

0.027 - 0.029

52 Week Range

0.015 - 0.057

Volume

1,986,208

Value

55,109

Bid

0.028

Ask

0.029

Dividend Yield

0.00%

P/E Ratio

0.00

Market Cap

65.154M

Total Issue

2,326,921,261

ASX Announcements

Notification regarding unquoted securities - ACW

Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)

  • May 14, 2024
  • 6 pages

Cleansing Notice

Cleansing Notice

  • May 14, 2024
  • 1 page

Application for quotation of securities - ACW

Appendix 2A (Application for Quotation of Securities)

  • May 14, 2024
  • 6 pages

ACW Clinical Trials Science Forum 23 May registration detail

Company Administration - Other, Web Casts

  • May 13, 2024
  • 3 pages

Application for quotation of securities - ACW

Appendix 2A (Application for Quotation of Securities)

  • May 8, 2024
  • 6 pages

View all ACW announcements

October 2020

Actinogen Medical shares are in a trading halt while its broker seeks buyers for new shares in the company.

Bell Potter raising for Alzheimer's drug hopeful Actinogen

ASX-listed Actinogen Medical is in front of potential investors seeking a $10 million equity injection to fund a trial for its Alzheimer's drug. 

  • Sarah Thompson, Anthony Macdonald and Tim Boyd

December 2017

Actinogen Medical raises $5.2m for Alzheimer's treatment

Alzheimer's disease is the second biggest killer of Australians, but investors have just bet $5.3 million that an ASX-listed company has the cure.

  • Michael Bailey

January 2016

  • Opinion
The medical industry is turning to treating diseases of the brain; we should also see a boom in brain medicine, thanks to scientific advances.

In innovation and biotech let's party like it's 1998

Conditions may be bad but in 1997 they were also bad and 1998 was expected to be far worse, but then the sharemarket boomed.

  • Updated
  • Martin Rogers

Copyright © 2024. Company information displayed on The Australian Financial Review is sourced from Morningstar and ASX and is subject to their terms and conditions as set out in our Terms of Use. The Australian Financial Review does not accept any responsibility for the accuracy and/or completeness of such data or information.